Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Capital Expenditures (2020 - 2025)

Bioventus' Capital Expenditures history spans 6 years, with the latest figure at -$1.7 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 295.07% year-over-year to -$1.7 million; the TTM value through Dec 2025 reached $240000.0, down 76.14%, while the annual FY2025 figure was $240000.0, 76.14% down from the prior year.
  • Capital Expenditures reached -$1.7 million in Q4 2025 per BVS's latest filing, down from $473000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $6.0 million in Q3 2023 to a low of -$5.7 million in Q4 2023.
  • Average Capital Expenditures over 5 years is $183550.0, with a median of $224000.0 recorded in 2021.
  • The largest YoY upside for Capital Expenditures was 4584.21% in 2023 against a maximum downside of 28700.0% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at -$3.9 million in 2021, then surged by 78.03% to -$851000.0 in 2022, then plummeted by 567.69% to -$5.7 million in 2023, then surged by 115.72% to $893000.0 in 2024, then plummeted by 295.07% to -$1.7 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Capital Expenditures are -$1.7 million (Q4 2025), $473000.0 (Q3 2025), and $683000.0 (Q2 2025).